MX2020006225A - Constructos antigenicos del virus de epstein-barr. - Google Patents
Constructos antigenicos del virus de epstein-barr.Info
- Publication number
- MX2020006225A MX2020006225A MX2020006225A MX2020006225A MX2020006225A MX 2020006225 A MX2020006225 A MX 2020006225A MX 2020006225 A MX2020006225 A MX 2020006225A MX 2020006225 A MX2020006225 A MX 2020006225A MX 2020006225 A MX2020006225 A MX 2020006225A
- Authority
- MX
- Mexico
- Prior art keywords
- epstein
- barr virus
- virus antigen
- antigen constructs
- constructs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16271—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invención proporciona polinucleótidos, polipéptidos y vectores antigénicos del virus de Epstein-Barr; así como composiciones inmunogénicas que lo comprenden. Incluye el uso de constructos antigénicos del virus de Epstein-Barr para producir vacunas, con el fin de tratar y prevenir las infecciones del virus de Epstein-Barr y las enfermedades asociadas al virus de Epstein-Barr, como la esclerosis múltiple, la artritis reumatoide y el lupus eritematoso sistémico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762608038P | 2017-12-20 | 2017-12-20 | |
PCT/IB2018/060101 WO2019123169A1 (en) | 2017-12-20 | 2018-12-14 | Epstein-barr virus antigen constructs |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020006225A true MX2020006225A (es) | 2020-12-07 |
Family
ID=65363319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006225A MX2020006225A (es) | 2017-12-20 | 2018-12-14 | Constructos antigenicos del virus de epstein-barr. |
Country Status (13)
Country | Link |
---|---|
US (2) | US11773139B2 (es) |
EP (1) | EP3728291A1 (es) |
JP (2) | JP2021507712A (es) |
KR (1) | KR20200101394A (es) |
CN (1) | CN111801342A (es) |
AU (1) | AU2018392884B2 (es) |
BR (1) | BR112020012361A2 (es) |
CA (1) | CA3085975A1 (es) |
EA (1) | EA202091178A1 (es) |
IL (1) | IL275296A (es) |
MX (1) | MX2020006225A (es) |
SG (1) | SG11202005451SA (es) |
WO (1) | WO2019123169A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111394376B (zh) * | 2020-03-30 | 2023-04-28 | 济宁医学院 | 一种融合基因bfna、重组腺病毒及其制备方法和应用 |
WO2023064612A2 (en) * | 2021-10-15 | 2023-04-20 | BioNTech SE | Pharmaceutical compositions for delivery of viral antigens and related methods |
WO2024003239A1 (en) * | 2022-06-29 | 2024-01-04 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN |
WO2024084091A1 (en) | 2022-10-21 | 2024-04-25 | Medizinische Universität Wien | Materials and methods to treat epstein-barr virus (ebv) and ebv-induced diseases |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4427117C1 (de) * | 1994-07-30 | 1995-10-19 | Gsf Forschungszentrum Umwelt | Plasmid und damit transfizierte Zellen |
US5716845A (en) | 1995-07-20 | 1998-02-10 | Wisconsin Alumni Research Foundation | Immortalized lymphocytes for production of viral-free proteins |
CA2154854C (en) * | 1994-07-30 | 2006-03-14 | William M. Sugden | Immortalized lymphocytes for production of viral-free proteins |
US6083716A (en) | 1996-09-06 | 2000-07-04 | The Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
AU756081B2 (en) * | 1997-07-10 | 2003-01-02 | Council Of The Queensland Institute Of Medical Research, The | CTL epitopes from EBV |
US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
ES2256323T5 (es) | 2000-11-23 | 2016-11-21 | Bavarian Nordic A/S | Variante del virus Vaccinia Ankara Modificado |
HU228327B1 (en) | 2001-06-22 | 2013-03-28 | Wistar Inst | Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
ATE449105T1 (de) | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
JP4896021B2 (ja) | 2004-05-21 | 2012-03-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | 呼吸器系病原体ワクチンのためのアルファウイルスベクター |
FR2881746B1 (fr) * | 2005-02-07 | 2007-04-13 | Centre Nat Rech Scient | Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications |
JP4824389B2 (ja) * | 2005-10-28 | 2011-11-30 | 株式会社医学生物学研究所 | エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性t細胞エピトープペプチド及びその用途 |
AU2006338570B2 (en) | 2005-11-18 | 2013-07-11 | The Ohio State University Research Foundation | Viral gene products and methods for vaccination to prevent viral associated diseases |
CA2632402A1 (en) | 2005-12-06 | 2007-06-14 | Savine Therapeutics Pty Ltd | Treatment of epstein-barr virus-associated diseases |
US20090324630A1 (en) * | 2008-04-21 | 2009-12-31 | Jensen Michael C | Fusion multiviral chimeric antigen |
SG172935A1 (en) | 2009-02-02 | 2011-08-29 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
WO2011005799A2 (en) | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
ES2770335T3 (es) | 2010-07-06 | 2020-07-01 | Glaxosmithkline Biologicals Sa | Administración de ARN para desencadenar múltiples vías inmunológicas |
EP4180057A1 (en) | 2010-07-06 | 2023-05-17 | GlaxoSmithKline Biologicals S.A. | Virion-like delivery particles for self-replicating rna molecules |
WO2012048817A2 (en) | 2010-10-15 | 2012-04-19 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara influenza vaccine |
WO2012089231A1 (en) | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
JP6091435B2 (ja) | 2011-02-22 | 2017-03-08 | カリフォルニア インスティチュート オブ テクノロジー | アデノ随伴ウイルス(aav)ベクターを用いたタンパク質の送達 |
CN110038135B (zh) * | 2011-03-17 | 2021-03-05 | 伯明翰大学 | 重新定向的免疫治疗 |
JP2014522842A (ja) | 2011-07-06 | 2014-09-08 | ノバルティス アーゲー | 免疫原性組み合わせ組成物およびその使用 |
EP2729168A2 (en) | 2011-07-06 | 2014-05-14 | Novartis AG | Immunogenic compositions and uses thereof |
CA3158572A1 (en) | 2012-08-01 | 2014-02-06 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine |
EP3872097A1 (en) * | 2012-10-19 | 2021-09-01 | The Council Of The Queensland Institute Of Medical Research | Improved human herpesvirus immunotherapy |
GB201312133D0 (en) * | 2013-07-05 | 2013-08-21 | Univ Birmingham | Immunotherapy |
EP3054971B1 (en) * | 2013-10-11 | 2021-03-10 | The United States of America, represented by the Secretary, Department of Health and Human Services | Epstein-barr virus vaccines |
EP3888676A1 (en) | 2014-06-13 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Immunogenic combinations |
WO2016149384A1 (en) * | 2015-03-18 | 2016-09-22 | University Of Massachusetts | Virus-like particle compositions and vaccines against epstein-barr virus infection and disease |
CN108025058B (zh) * | 2015-06-12 | 2022-12-16 | 葛兰素史密丝克莱恩生物有限公司 | 腺病毒多核苷酸和多肽 |
WO2019055887A1 (en) * | 2017-09-16 | 2019-03-21 | City Of Hope | PSEUDO-VIRAL PARTICLES OF MULTIVALENT EPSTEIN-BARR VIRUS AND USES THEREOF |
-
2018
- 2018-12-14 US US16/770,963 patent/US11773139B2/en active Active
- 2018-12-14 MX MX2020006225A patent/MX2020006225A/es unknown
- 2018-12-14 EP EP18845444.1A patent/EP3728291A1/en active Pending
- 2018-12-14 JP JP2020534609A patent/JP2021507712A/ja active Pending
- 2018-12-14 CN CN201880089867.5A patent/CN111801342A/zh active Pending
- 2018-12-14 WO PCT/IB2018/060101 patent/WO2019123169A1/en unknown
- 2018-12-14 BR BR112020012361-7A patent/BR112020012361A2/pt unknown
- 2018-12-14 CA CA3085975A patent/CA3085975A1/en active Pending
- 2018-12-14 SG SG11202005451SA patent/SG11202005451SA/en unknown
- 2018-12-14 EA EA202091178A patent/EA202091178A1/ru unknown
- 2018-12-14 AU AU2018392884A patent/AU2018392884B2/en not_active Ceased
- 2018-12-14 KR KR1020207020466A patent/KR20200101394A/ko not_active Application Discontinuation
-
2020
- 2020-06-11 IL IL275296A patent/IL275296A/en unknown
-
2023
- 2023-07-25 US US18/358,350 patent/US20240076318A1/en active Pending
- 2023-08-02 JP JP2023126388A patent/JP2023145678A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11202005451SA (en) | 2020-07-29 |
KR20200101394A (ko) | 2020-08-27 |
US20210198321A1 (en) | 2021-07-01 |
CA3085975A1 (en) | 2019-06-27 |
IL275296A (en) | 2020-07-30 |
EP3728291A1 (en) | 2020-10-28 |
US20240076318A1 (en) | 2024-03-07 |
JP2021507712A (ja) | 2021-02-25 |
AU2018392884A1 (en) | 2020-06-25 |
JP2023145678A (ja) | 2023-10-11 |
US11773139B2 (en) | 2023-10-03 |
EA202091178A1 (ru) | 2020-09-01 |
WO2019123169A1 (en) | 2019-06-27 |
AU2018392884B2 (en) | 2021-11-11 |
BR112020012361A2 (pt) | 2020-11-24 |
CN111801342A (zh) | 2020-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020006225A (es) | Constructos antigenicos del virus de epstein-barr. | |
PH12018501281A1 (en) | Human immunodeficiency virus neutralizing antibodies | |
ZA202000373B (en) | Anti-cd47 antibodies and uses thereof | |
PH12019501812A1 (en) | Compositions and methods for the treatment of hemoglobinopathies | |
MX2016010954A (es) | Construcciones de proteina superficial ubicua a2 y usos de las mismas. | |
MX2019012223A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
ZA201803978B (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
EA201991431A1 (ru) | УСИЛЕННЫЙ ОПОСРЕДОВАННЫЙ ТРАНСПОЗОНАМИ СЕМЕЙСТВА hAT ПЕРЕНОС ГЕНОВ И АССОЦИИРОВАННЫЕ КОМПОЗИЦИИ, СИСТЕМЫ И СПОСОБЫ | |
MX2018002106A (es) | Vacunas terapeuticas contra el hpv18. | |
CY1122265T1 (el) | Αντισωματα εναντι ταυ και χρησεις αυτων | |
MX2016009625A (es) | Proteinas quimericas tipo fosfatasa alcalina. | |
MX2017014550A (es) | Inhibidores del antigeno nuclear epstein-barr 1 (ebna1) y metodos que los utilizan. | |
PH12018502332A1 (en) | Stabilized pre-fusion rsv f proteins | |
MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
NZ722518A (en) | Il-21 antibodies | |
SG11202002737PA (en) | Adeno-associated virus compositions for restoring hbb gene function and methods of use thereof | |
MX356325B (es) | Composicion para cuidado personal. | |
TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
PH12019500903A1 (en) | Isolation of a novel pestivirus causing congenital tremor a | |
WO2018183692A8 (en) | VECTORS AND COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | |
PT3440208T (pt) | Vetores para clonagem e expressão de proteínas, métodos e suas aplicações | |
MX2016013471A (es) | Composicion para el cuidado personal. | |
PH12017500776B1 (en) | Antiperspirant composition | |
PL412612A1 (pl) | Szczep Gram-dodatniej laseczki Bacillus subtillis, rekombinowane przetrwalniki, kompozycja immunogenna, doustna szczepionka oraz jej zastosowanie przeciwko wirusowi grypy typu A |